New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Scribe Therapeutics Inc.

SCTX

Healthcare Biotechnology

Scribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.

12.07 1.15 −8.70%

After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.

Market cap
$250.4M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
—
Payout ratio
—

What it owns vs. what it owes Q3 FY2026, Sep 30, 2026

Shareholders’ equity is 66.6% of the balance sheet. What is a balance sheet?

Sep 30, 2026 · total $187.9M

Owns

$9.0MLong-term assets
$4.7MOther short-term assets
$174.2MCash & short-term investments

Funded by

$125.2MShareholders’ equity
$62.8MOther liabilities

Debt is 0.00% of the total; shareholders’ equity 66.6%.

Sep '26 Jun '26 Dec '25 Sep '25 Older periods
Total current assets
178.89 45.11 66.93 —
Total non-current assets
9.04 12.82 11.29 —
Total Assets
187.93 57.93 78.22 —
Total current liabilities
37.93 78.70 69.06 —
Total non-current liabilities
24.83 23.72 32.23 —
Total liabilities
62.76 102.42 101.28 —
Common Equity (Total)
125.17 (164.85) (143.42) —
Shareholders Equity (Total)
125.17 (44.49) (23.06) —

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026